PARSIPPANY, N.J., Sept. 19, 2011 /PRNewswire/ — Watson
Pharmaceuticals, Inc. (NYSE:
WPI) today announced that Amphastar Pharmaceuticals, Inc., has
received U.S. Food and Drug Administration (“FDA”) approval of its
Abbreviated New Drug Application (ANDA) for Enoxaparin Sodium
Injection in the 100mg/mL and 150mg/mL strengths. Enoxaparin
Sodium Injection is the generic equivalent to Sanofi-aventis’
LOVENOX®, and is a low molecular weight heparin indicated in
the prophylaxis and treatment of deep vein thrombosis and
prophylaxis of ischemic complications in unstable angina and
non-Q-wave myocardial infarction.
Pursuant to the terms of the parties’ exclusive Distribution
Agreement, Amphastar will supply Enoxaparin Sodium Injection to
Watson, which will market, sell and distribute the product to the
U.S. retail pharmacy channel. Amphastar will receive between
50 and 55 percent of Watson’s gross profits on product sales,
depending on the number of competitors in the market.
Amphastar will market, sell and distribute the product to all
other channels. For the 12-months ending July 30, 2011,
LOVENOX® and its generic equivalents had total U.S. sales of
approximately $2.6 billion, according to IMS Health.
Amphastar is currently preparing for launch and anticipates
launching its Enoxaparin Sodium Injection product in the fourth
quarter of 2011.
About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals,
Inc. is an integrated global specialty pharmaceutical company. The
Company is engaged in the development, manufacturing, marketing and
distribution of generic pharmaceuticals and specialized branded
pharmaceutical products focused on Urology and Women’s Health.
Watson has operations in many of the world’s established and
growing international markets.
For press release and other company information, visit Watson